Teva’s Laquinimod MS Pill Fails to Win EU Agency Backing

Teva Pharmaceutical Industries Ltd. failed to win backing from the European Union drug regulator for a new multiple sclerosis pill, hurting the company’s effort to introduce a successor to its best-selling injection Copaxone.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.